CAR T-Cell Therapy Opportunity within Follicular Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 CAR T-Cell Therapy Opportunity within Follicular Lymphoma Market Outlook

Thelansis’s “CAR T-Cell Therapy Opportunity within Follicular Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CAR T-Cell Therapy Opportunity within Follicular Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

CAR T-Cell Therapy Opportunity within Follicular Lymphoma Overview

Follicular lymphoma (FL) is the second most commonly diagnosed, typically affecting individuals around 65 at presentation. Approximately 80% of patients with FL have a chromosomal abnormality known as t(14;18), which leads to the overexpression of the B-cell lymphoma 2 (BCL-2) protein. Most patients with low-grade FL (grade 1, 2, or 3A) are diagnosed at an advanced disease stage. However, treatment may not be necessary unless patients develop symptoms, organ function impairment, or symptomatic cytopenias. When treatment is required for patients with advanced-stage FL, several chemoimmunotherapeutic combinations can be used are, include rituximab or obinutuzumab with cyclophosphamide, vincristine, and prednisone (CVP); rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-R); or bendamustine plus rituximab (BR) or obinutuzumab, which have shown non-inferiority to conventional chemoimmunotherapy regimens. Another option is the combination of lenalidomide and rituximab. Patients who experience disease progression early (within 24 months) after initial first-line treatment containing anti-CD20 monoclonal antibody (POD24) tend to have poor outcomes. The treatment choice for patients with relapsed or refractory (R/R) FL depends on the aggressiveness and clinical presentation of the disease, along with the patient’s performance status and existing comorbidities. Second-line and beyond treatment options include chemoimmunotherapy, radioimmunotherapy, phosphoinositide 3-kinase inhibitors (PI3Kis), tazemetostat (an inhibitor of enhancer of zeste homolog 2 – EZH2), and in some cases, autologous (auto-HCT) or allogeneic (allo-HCT) hematopoietic cell transplant. The prognosis for patients with R/R FL is generally poor, with expected short progression-free and overall survival. In the United States, two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel, are approved for treating R/R FL. Tisagenlecleucel was granted accelerated approval by the FDA in May 2022 for treating adults with R/R FL after failing two or more lines of systemic therapy.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: CAR T-Cell Therapy Opportunity within Follicular Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034